Maelstrom Research Staging | CPDDN_PhaseI_DemyelinatingChildren_Follow-up

CPDDN_PhaseI_DemyelinatingChildren_Follow-up_14years

Networks -

Variables -

Associated study CPDDN Contingency Table

Population

CPDDN - Phase I (Demyelinating Children)

The population is composed of Canadian children aged younger than 16 years who presented acquired demyelinating syndrome (ADS), to any of the 16 paediatric health-care facilities or seven regional health-care facilities in Canada and were enrolled within 90 days of symptom onset.

Selection Criteria

Maximum age

Newborns

Twins

Countries

Canada

Territory

Victoria, Vancouver, Calgary, Edmonton, Saskatoon, Winnipeg, Windsor, London, Mississauga, Ottawa, Hamilton, Toronto, Montreal, Sherbrooke, Kingston, St. John's, Saint John, and Halifax

Ethnic Origin

Health Status

Meet criteria for acquired demyelinating syndromes (ADS)

Supplementary Information about selection criteria

Recruitment

Sources of recruitment

Specific population

Specific Population

Clinic patients

Supplementary Information

Patients from all 24 pediatric health care institutions in Canada are invited to participate in the study at the time of their first demyelinating attack within 90 days of symptom onset.

Number of Participants

Number of Participants: 302
Number of Participants with Biological Samples
Supplementary Information about selection criteria

More info

Data Collection Event

CPDDN - Phase I (Demyelinating Children) - Follow-up 14 years

Information was collected from participants and/or guardian through interviews which collected information about medications, smoke exposure, travel history, family, education. Additionally, questionnaires were used to collect the PedsQL, Barratt Simplified Measure of Social Status, Paediatric Index of Emotional Distress, the HADS, Godin Leisure Time Exercise, Physical Activity Self Efficacy Scale, and Exercise Goal Setting Scale. Clinicians provided information on medication usage, episodes, and conducted a neurological exam. Neurocognitive batteries were conducted in-person. MRI data were also collected in MS children only. Blood was collected for serum, DNA and PBMCs.

More info

Collected Dataset / CPDDN_PhaseI_DemyelinatingChildren_Follow-up_14years

CPDDN_PhaseI_DemyelinatingChildren_Follow-up_14years

Population

CPDDN - Phase I (Demyelinating Children)

Data Collection Event

CPDDN - Phase I (Demyelinating Children) - Follow-up 14 years

Files

Variables Classifications